Conditions: Endocrine Tumors
Keywords: Non functioning entero-pancreatic tumours
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 264
Healthy volunteers: no

Brief summary:
The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: lanreotide (Autogel formulation) intervention 2: Placebo
Intervention descriptions: intervention 1: 120mg administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks. intervention 2: Saline solution 0.9% administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.

Protocol document: